The early luteal hormonal profile in IVF patients triggered with hCG

2020 ◽  
Vol 35 (1) ◽  
pp. 157-166 ◽  
Author(s):  
Lan N Vuong ◽  
Tuong M Ho ◽  
Toan D Pham ◽  
Vu N A Ho ◽  
Claus Yding Andersen ◽  
...  

Abstract STUDY QUESTION What is the early luteal phase hormonal profile in patients undergoing ovarian stimulation for IVF/ICSI followed by hCG trigger and a freeze-all strategy without luteal phase support? SUMMARY ANSWER The peak concentration of progesterone occurred 4 days after oocyte pick-up (OPU + 4), with an average 35% fall from OPU + 4 to OPU + 6, and progesterone levels before and 12 h after hCG administration predicted levels during the early luteal phase. WHAT IS KNOWN ALREADY The luteal phase during IVF differs from that during normal cycles, particularly with respect to the serum progesterone level profile. This can cause asynchrony between the embryo and the endometrium, potentially resulting in implantation failure and poor reproductive outcomes. STUDY DESIGN, SIZE, DURATION This prospective study included 161 women with normal ovarian reserve receiving GnRH antagonist co-treatment during ovarian stimulation with FSH who were followed up to 6 days after OPU in a single IVF cycle. PARTICIPANTS/MATERIALS, SETTING, METHODS Women aged 18–42 years undergoing IVF with ovarian stimulation using FSH were included. Ovulation was triggered with recombinant hCG 250 μg. Hormone levels were determined from blood samples taken on the day of trigger, before hCG, at 12, 24 and 36 h after hCG and at 1, 2, 3, 4, 5 and 6 days after OPU. The primary endpoint was early luteal phase serum concentrations of progesterone, LH, estradiol and hCG. MAIN RESULTS AND THE ROLE OF CHANCE One outlier with a pre-hCG serum progesterone level of 11.42 ng/mL was excluded, so all analyses included 160 subjects. Progesterone levels began to increase 1 day after OPU, peaked 4 days after OPU (114 ng/mL), then declined from OPU + 5 onwards. Peak progesterone levels were at OPU + 4, OPU + 5 or OPU + 6 in 38.8, 29.4 and 13.8% of patients, respectively. Approximately two-thirds of patients had a fall in serum progesterone from OPU + 4 to OPU + 6. Pre-hCG progesterone levels correlated significantly with those at 24 h after hCG (r2 = 0.28; P < 0.001), which in turn correlated significantly with progesterone at OPU + 4 (r2 = 0.32; P < 0.001). LH peaked (4.4 IU/L) 12 h after hCG trigger, persisting for 24 h but was barely elevated compared with physiological levels. Serum estradiol peaked twice: at 24 h post-trigger and at OPU + 4. Highest hCG levels (130 mIU/mL) occurred at 24 h post-injection. The best correlations between the number of follicles ≥11 mm and serum progesterone level were seen at 24 and 36 h after hCG and OPU + 1. LIMITATIONS, REASONS FOR CAUTION The influence of different profiles of serum progesterone on reproductive outcomes could not be determined because a freeze-all strategy was used in all patients. In addition, data were not available to relate serum hormone level findings with endometrial histology or endometrial receptivity analysis to clearly identify the relationship between serum hormones and the window of implantation. WIDER IMPLICATIONS OF THE FINDINGS Detailed information about early luteal phase hormone levels could be used to optimize and individualize luteal phase support to improve reproductive outcomes. STUDY FUNDING/COMPETING INTEREST(S) This study was funded by My Duc Hospital, Ho Chi Minh City, Vietnam. All authors state that they have no conflicts of interest to disclose. TRIAL REGISTRATION NUMBER NCT02798146; NCT03174691.

PLoS ONE ◽  
2019 ◽  
Vol 14 (7) ◽  
pp. e0220450 ◽  
Author(s):  
Antoine Netter ◽  
Julien Mancini ◽  
Christophe Buffat ◽  
Aubert Agostini ◽  
Jeanne Perrin ◽  
...  

2016 ◽  
pp. 809-814
Author(s):  
K. DAFOPOULOS ◽  
C. I. MESSINI ◽  
G. ANIFANDIS ◽  
P. GEORGOULIAS ◽  
D. SOURLAS ◽  
...  

The aim of the present study was to investigate changes of blood ghrelin, adiponectin and resistin levels in IVF/ICSI-ET cycles. Twenty women were stimulated with recombinant FSH in a GnRH agonist short protocol for IVF/ICSI. Blood samples were taken on cycle day 2 before the commencement of injections, on cycle day 6 and on the days of HCG injection, oocyte pick up (OPU), embryo transfer (ET) as well as 7 and 12 days post-ET. Serum E2 levels increased during the stimulation, peaking on the HCG day and declined thereafter (p<0.001). Serum progesterone levels started to increase on the OPU day, peaking on the ET day (p<0.001) and decreased on days 7 and 12 post-ET. Plasma ghrelin remained unchanged during the whole cycle. Serum adiponectin levels remained stable during the stimulation period until the ET day and decreased on days 7 and 12 post-ET (p<0.001). Serum resistin levels increased until the ET day (p<0.05), remained unchanged on day 7 post-ET and decreased on day 12 post-ET (p<0.05). The present study shows for the first time that ghrelin levels did not change significantly during IVF/ICSI-ET cycles. Resistin levels increased during the stimulation period while adiponectin levels remained stable decreasing during the luteal phase.


Author(s):  
Steve Pawsey ◽  
Edouard Gregory Mills ◽  
Elizabeth Ballantyne ◽  
Kirsteen Donaldson ◽  
Mary Kerr ◽  
...  

Abstract Context The ideal therapy for endometriosis (EM) and uterine fibroids (UF) would suppress estrogenic drive to the endometrium and myometrium, whilst minimizing vasomotor symptoms and bone loss associated with current treatments. An integrated neurokinin-kisspeptin system involving Substance P and neurokinin B acting at the neurokinin (NK) receptors 1 and 3, respectively, modulates reproductive hormone secretion and represents a therapeutic target. Objective To assess the effects of the novel NK1,3 antagonist elinzanetant on reproductive hormone levels in healthy women. Design Randomized, single-blinded, placebo-controlled study. Participants/Intervention Thirty-three women attended for 2 consecutive menstrual cycles. In each cycle blood samples were taken on days 3/4, 9/10, 15/16 and 21/22 to measure serum reproductive hormones. In cycle 2, women were randomized to receive once daily oral elinzanetant 40, 80, 120 mg or placebo (N=8 or 9 per group). Results Elinzanetant dose-dependently lowered serum luteinizing hormone, estradiol (120 mg median change across cycle: -141.4 pmol/L, P=0.038) and luteal phase progesterone (120 mg change from baseline on day 21/22: -19.400 nmol/L, P=0.046). Elinzanetant 120 mg prolonged the cycle length by median of 7.0 days (P=0.023). Elinzanetant reduced the proportion of women with a luteal phase serum progesterone concentration &gt;30 nmol/L (a concentration consistent with ovulation) in a dose-related manner in cycle 2 (P=0.002). Treatment did not produce vasomotor symptoms. Conclusions NK1,3 receptor antagonism with elinzanetant dose-dependently suppressed the reproductive axis in healthy women, with the 120 mg dose lowering estradiol to potentially ideal levels for UF and EM. As such, elinzanetant may represent a novel therapy to manipulate reproductive hormone levels in women with hormone driven disorders.


2012 ◽  
Vol 10 (1) ◽  
pp. 72 ◽  
Author(s):  
Yulian Zhao ◽  
Howard Zacur ◽  
Chris Cheadle ◽  
Ning Ning ◽  
Jinshui Fan ◽  
...  

1970 ◽  
Vol 6 (2) ◽  
pp. 116-121 ◽  
Author(s):  
Zinat Ara Polly ◽  
Shelina Begum ◽  
Sultana Ferdousi ◽  
Noorzahan Begum ◽  
Taskina Ali ◽  
...  

Background: Deterioration of lung function is common in women after menopause, which may be related to very low estrogen and progesterone level. Objective: To observe FEF25-75, PEFR and SVC (slow vital capacity) values in apparently healthy postmenopausal women to find out their relationships with serum estrogen and progesterone. Methods: This study was carried out in the Department of Physiology in BSMMU, Dhaka in the year 2007. 30 healthy postmenopausal women aged 45 to 60 years and 30 healthy premenopausal women aged 20 to 30 years during their different phases of menstrual cycle were studied. Postmenopausal women were residents of Dhaka city and premenopausal subjects were medical students. FEF25-75, PEFR and SVC of all subjects were measured by a digital micro spirometer. Their estrogen and progesterone levels were estimated by Micro particle Enzyme Immunoassay (MEIA) method. Data were analyzed by Pearson’s correlation coefficient test, one way ANOVA and unpaired‘t’ test Results: The mean percentage of predicted values of FEF25-75 and PEFR were lower in postmenopausal women compared to those of follicular and luteal phases of premenopausal women but it was not significant. Measured values of SVC was Significantly (p<.001) lower in postmenopausal women compared to those of follicular and luteal phases of premenopausal women. Again Mean serum estrogen and progesterone levels were significantly (p<.001) lower in post menopausal women compared to those of follicular and luteal phases of premenopausal women. In post menopausal women, FEF25-75 was positively, PEFR and SVC were negatively correlated with progesterone level. PEFR and SVC showed positive correlattion and FEF25-75 showed negative correlation with serum estrogen level. All these correlations were statistically non significant. In premenopausal women FEF25-75 and PEFR showed positive correlation and SVC showed negative correlation with serum progesterone level. The relationships were statistically significant in luteal phase but nonsignificant in follicular phase. FEF25-75 ,PEFR and SVC were positively correlated with serum estrogen level in luteal phase but FEF25-75 and PEFR negatively correlated and SVC positively correlated with estrogen level in follicular phase. Conclusion: The outcome of this study shows FEF25-75 , PEFR and SVC may be reduced in postmenopausal women which in turn may be associated with their low progesterone and estrogen levels. DOI: http://dx.doi.org/10.3329/jbsp.v6i2.9761 JBSP 2011 6(2): 116-121


Sign in / Sign up

Export Citation Format

Share Document